L3 Technologies, Inc. (LLL) Forms $184.00 Double Top; Depomed (DEPO) Shorts Up By 0.26%

Depomed, Inc. (NASDAQ:DEPO) Logo

Depomed Inc (NASDAQ:DEPO) had an increase of 0.26% in short interest. DEPO’s SI was 10.15M shares in May as released by FINRA. Its up 0.26% from 10.12M shares previously. With 846,900 avg volume, 12 days are for Depomed Inc (NASDAQ:DEPO)’s short sellers to cover DEPO’s short positions. The SI to Depomed Inc’s float is 21.84%. The stock decreased 1.00% or $0.06 during the last trading session, reaching $5.93. About 921,410 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 57.25% since May 7, 2017 and is downtrending. It has underperformed by 68.80% the S&P500.

L3 Technologies, Inc. (LLL) formed double top with $191.36 target or 4.00% above today’s $184.00 share price. L3 Technologies, Inc. (LLL) has $14.44 billion valuation. The stock increased 0.42% or $0.77 during the last trading session, reaching $184. About 1.09M shares traded or 55.74% up from the average. L3 Technologies, Inc. (NYSE:LLL) has risen 23.75% since May 7, 2017 and is uptrending. It has outperformed by 12.20% the S&P500.

Since December 14, 2017, it had 1 buying transaction, and 1 sale for $312,485 activity. Shares for $612,000 were bought by HIGGINS ARTHUR J. Gosling Matthew M had sold 45,519 shares worth $299,515.

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 52 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Hold” rating given on Friday, October 27 by RBC Capital Markets. The rating was initiated by Leerink Swann with “Outperform” on Thursday, March 10. Piper Jaffray initiated it with “Overweight” rating and $23 target in Monday, February 8 report. The rating was maintained by Mizuho on Tuesday, August 8 with “Hold”. On Monday, September 19 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Mizuho with “Buy” on Thursday, February 25. As per Monday, December 12, the company rating was downgraded by Piper Jaffray. The company was maintained on Wednesday, October 11 by Mizuho. The company was maintained on Friday, July 24 by WallachBeth Capital. The stock has “Hold” rating by Piper Jaffray on Friday, July 14.

Investors sentiment decreased to 0.93 in 2017 Q4. Its down 0.28, from 1.21 in 2017Q3. It turned negative, as 28 investors sold Depomed, Inc. shares while 47 reduced holdings. 24 funds opened positions while 46 raised stakes. 55.87 million shares or 0.97% less from 56.42 million shares in 2017Q3 were reported. Invesco Ltd, Georgia-based fund reported 244,633 shares. Mason Street Advsr Ltd Company holds 0% or 16,376 shares. Citadel Advsr Lc, a Illinois-based fund reported 18,661 shares. Louisiana State Employees Retirement Sys reported 27,100 shares. Numeric holds 32,009 shares or 0% of its portfolio. Millennium Mngmt holds 0.02% or 1.90M shares. Commercial Bank Of Montreal Can owns 6,420 shares. State Of Tennessee Treasury Department stated it has 0% in Depomed, Inc. (NASDAQ:DEPO). Driehaus Mgmt Ltd has invested 0.01% in Depomed, Inc. (NASDAQ:DEPO). 15,835 are owned by Jane Street Grp Llc. Globeflex Limited Partnership invested in 0.13% or 59,953 shares. Moreover, California State Teachers Retirement System has 0% invested in Depomed, Inc. (NASDAQ:DEPO) for 90,931 shares. 14,596 were accumulated by Cim Invest Mangement. Ameritas Invest Partners invested in 5,272 shares or 0% of the stock. Pacad Invest owns 36,300 shares.

Another recent and important Depomed, Inc. (NASDAQ:DEPO) news was published by Globenewswire.com which published an article titled: “Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on April 09, 2018.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $376.65 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.

Investors sentiment increased to 0.83 in 2017 Q4. Its up 0.08, from 0.75 in 2017Q3. It increased, as 4 investors sold L3 Technologies, Inc. shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 183,126 shares or 22.81% less from 237,250 shares in 2017Q3 were reported. Naples Glob Limited Company stated it has 0.11% of its portfolio in L3 Technologies, Inc. (NYSE:LLL). 162,939 were accumulated by Cibc Ww Corp. Stanley invested 0.19% in L3 Technologies, Inc. (NYSE:LLL). Oak Associates Oh holds 2,150 shares or 0.03% of its portfolio. West Oak Limited Liability has invested 0.01% in L3 Technologies, Inc. (NYSE:LLL). 1,530 are owned by Hanseatic Management. Covington Invest Inc holds 2,585 shares or 0.17% of its portfolio. 4,750 were accumulated by Wedgewood Pa. Gemmer Asset Management Limited Liability Corp invested in 77 shares or 0.01% of the stock.

Among 14 analysts covering L-3 Communications (NYSE:LLL), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. L-3 Communications had 60 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, December 9 report. The firm has “Buy” rating by Citigroup given on Tuesday, September 6. The firm earned “Hold” rating on Friday, October 27 by Stifel Nicolaus. The stock of L3 Technologies, Inc. (NYSE:LLL) earned “Overweight” rating by JP Morgan on Thursday, August 25. The stock has “Buy” rating by Cowen & Co on Friday, August 25. Jefferies maintained the stock with “Hold” rating in Thursday, January 25 report. The firm has “Buy” rating by Deutsche Bank given on Monday, December 5. The rating was upgraded by RBC Capital Markets on Wednesday, December 6 to “Outperform”. The stock of L3 Technologies, Inc. (NYSE:LLL) has “Equal Weight” rating given on Monday, May 2 by Barclays Capital. The firm has “Hold” rating by Jefferies given on Thursday, July 27.

Depomed, Inc. (NASDAQ:DEPO) Institutional Positions Chart